SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-008134
Filing Date
2024-05-14
Accepted
2024-05-14 16:08:23
Documents
72
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kala-20240331x10q.htm   iXBRL 10-Q 1963594
2 EX-31.1 kala-20240331xex31d1.htm EX-31.1 15191
3 EX-31.2 kala-20240331xex31d2.htm EX-31.2 15177
4 EX-32.1 kala-20240331xex32d1.htm EX-32.1 6698
5 EX-32.2 kala-20240331xex32d2.htm EX-32.2 6830
  Complete submission text file 0001558370-24-008134.txt   7390184

Data Files

Seq Description Document Type Size
6 EX-101.SCH kala-20240331.xsd EX-101.SCH 61117
7 EX-101.CAL kala-20240331_cal.xml EX-101.CAL 48393
8 EX-101.DEF kala-20240331_def.xml EX-101.DEF 276484
9 EX-101.LAB kala-20240331_lab.xml EX-101.LAB 509177
10 EX-101.PRE kala-20240331_pre.xml EX-101.PRE 389776
76 EXTRACTED XBRL INSTANCE DOCUMENT kala-20240331x10q_htm.xml XML 1016276
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38150 | Film No.: 24944349
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)